| Overview |
| bsm-51071M |
| MASTL (5C3) Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This MASTL monoclonal antibody is generated from mouse immunized with MASTL recombinant protein. |
| Monoclonal |
| #REF! |
| IgG1 |
| 0.5ug/ul |
| Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C for 12 months. |
| Target |
| 84930 |
| Q96GX5 |
| GW; GWL; THC2; MAST-L; GREATWALL; Serine/threonine-protein kinase greatwall; hGWL; Microtubule-associated serine/threonine-protein kinase-like; MASTL |
| Serine/threonine kinase that plays a key role in M phase by acting as a regulator of mitosis entry and maintenance. Acts by promoting the inactivation of protein phosphatase 2A (PP2A) during M phase: does not directly inhibit PP2A but acts by mediating phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-62' and 'Ser-67', respectively. ARPP19 and ENSA are phosphatase inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase is essential to keep cyclin-B1-CDK1 activity high. Following DNA damage, it is also involved in checkpoint recovery by being inhibited. Phosphorylates histone protein in vitro; however such activity is unsure in vivo. May be involved in megakaryocyte differentiation. |
| Application Dilution |
| WB |
1:300-5000 |